$HIND News

Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting

Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Announces Publication Of Preclinical Data For Uveitis Treatment VT-1908

Vyome Announces Publication Of Preclinical Data For Uveitis Treatment VT-1908

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Vyome Capitalizes VT-1953 Phase 3 Interim Results By Raising $5.29M Through Sale Of 1,089,045 Shares At $5.00

Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Down -9.32%

Vyome Shares Move Higher; Co Highlights Independent Analyst Valuation Of Vyome

We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate

Vyome Holdings' Subsidiary LiveChain Enters Binding LOI To Acquire Humanyze Convertible Note In Equity Exchange with Remus Capital

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Holdings Subsidiary, LiveChain, To Acquire Senior Secured Note In Humanyze; LiveChain To Issue Shares Of ~$325K In Exchanve

Vyome Holdings shares are trading higher after the company announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds.

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome's VT-1953 Announces Phase 2 Efficacy In Malignant Fungating Wounds, Paving Path To Pivotal Trial